generationbio.com - Multiplikator forward rega marang pendapatan GBIO
The financial stability of Generation Bio Co. (GBIO) relies on partnerships with industry leaders that guarantee reliable capital. On GURU.Markets, the forward price-to-sales ratio demonstrates asset valuation dynamics, where the 2.30 metric indicates the value status. Patents for synthetic carriers create a steep barrier to entry for competitors, while independence from macroeconomic trends makes the company a defensive asset during recessionary periods.
GBIO (generationbio.com): rincian analitis lan laporan miturut indikator
- rega pasar lan target rega analis:
- rincian nilai pasar emiten:
- rincian valuasi buku bisnis:
- informasi babagan utang lan solvabilitas:
Utang marang Ekuitas Generation Bio Co.|GBIO - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Generation Bio|GBIO - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku GBIO|GBIO - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Generation Bio|Indikator likuiditas cepet generationbio.com
- rincian asil keuangan lan kelipatan valuasi:
GBIO - Asil keuangan resik|Proyeksi bathi mangsa ngarep Generation Bio Co.|GBIO - Rasio kapitalisasi marang bathi resik|Pangali Forward P/E Generation Bio|GBIO - Rasio rega marang bathi tumrap wutah|Pangali EV/EBITDA GBIO|GBIO - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Generation Bio|GBIO - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan generationbio.com|GBIO - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Generation Bio Co.
- indikator pendapatan dodolan lan penghasilan bisnis:
Ringkesan analisis perusahaan:Generation Bio Corp GBIO
Forward P/S measures the market's emotional response to future revenue dynamics, allowing for an assessment of capital freeze risk amid high multiple volatility. The current value of 2.30 in the projected P/S trend reflects Generation Bio Co. (GBIO) lacking pricing power during the R&D stage; however, the potential of its unique non-lipid platform could eventually transform this valuation into a tool for market dominance.
Pesaing Generation Bio Co. (GBIO)
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|QGEN: Kapitalisasi marang prakiraan pendapatan|IONS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan RGEN (Repligen Inc.)|RNA: Multiplikator Forward P/S|CRSP (crisprtx.com) - Rasio rega marang prakiraan pendapatan|WGS (GeneDx) - Multiplikator Forward P/S|Ultragenyx Pharmaceutical Inc. (RARE) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Beam Therapeutics Corp (BEAM)|SRPT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Twist Bioscience - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan TXG|Intellia Therapeutics, Inc. - Multiplikator Forward P/S|Stoke Therapeutics Inc (STOK) - Multiplikator forward rega marang pendapatan|BioLife Corp (BLFS) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Wave Pharma (WVE)|Multiplikator forward rega marang pendapatan MAZE|sionnatx.com (SION) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S PRME|Taysha Gene Therapies Inc (TSHA) - Prakiraan rega marang pendapatan|Multiplikator Forward P/S QURE (uniQure Corp)|MeiraGTx Corp - Rasio rega marang prakiraan pendapatan|REGENXBIO Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake solidbio.com SLDB|Ocugen (OCGN) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pacific Biosciences of California, Inc. (PACB)|BNTC (Benitec) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan DSGN (Design Corp)|Rasio rega marang prakiraan pendapatan Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S LXEO (Lexeo Therapeutics, Inc.)|Multiplikator Forward P/S Korro Bio Inc. KRRO|Editas - Multiplikator Forward P/S|Prakiraan rega marang pendapatan Silence Therapeutics Corp (SLN)|PRQR: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Codexis (CDXS)|Rasio rega marang prakiraan pendapatan Sangamo Therapeutics, Inc.|Kapitalisasi marang prakiraan pendapatan NAUT (Nautilus Biotechnology Inc)|Multiplikator Forward P/S MGX|DTIL - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Boundless Bio, Inc. BOLD|Rega forward marang dodolan XCUR|Celsion Corporation - Multiplikator Forward P/S|PHIO - Multiplikator Forward P/S|MBIO (mustangbio.com) - Multiplikator forward rega marang pendapatan|RNAZ: Rasio rega marang pendapatan sing dikarepake|BNGO (Bionano Genomics Inc.) - Multiplikator Forward P/S|adnas.com (APDN) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan bluebird bio (BLUE)|IPA - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Omega OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (syros.com)|TBIO: Multiplikator Forward P/S|TCON (TRACON Pharmaceuticals Inc.) - Rasio rega marang prakiraan pendapatan|UBX (Unity Bio) - Multiplikator Forward P/S
